Quick Takeaways
- Squadron Capital Management LLC filed SCHEDULE 13G/A for Pasithea Therapeutics Corp. Common Stock, par value $0.0001 per share (KTTA).
- Disclosed ownership: 9.9%.
- Date of event: 31 Dec 2025.
Squadron Capital Management LLC - 31 Dec 2025 SCHEDULE 13G/A Report for Pasithea Therapeutics Corp. Common Stock, par value $0.0001 per share (KTTA)
- Filing Manager
- Squadron Capital Management LLC
- Reporting Manager
- Squadron Master Fund LP
- Symbol
- KTTA
- Shares outstanding
- 23,532,818 shares
- Disclosed Ownership
- 2,329,749 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 11:36:30 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 05 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Squadron Capital Management LLC disclosed 9.9% ownership in Pasithea Therapeutics Corp. Common Stock, par value $0.0001 per share (KTTA) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 05 Dec 2025.
- Current filing was accepted on 17 Feb 2026, 11:36.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Squadron Master Fund LP | 9.9% | 2,329,749 | 0 | 2,329,749 | /s/ Matthew Sesterhenn | Partner, Squadron Partners LLC, its General Partner | |
| Squadron Capital Management LLC | 9.9% | 2,329,749 | 0 | 2,329,749 | /s/ Matthew Sesterhenn | Partner | |
| Matthew Sesterhenn | 9.9% | 2,329,749 | 0 | 2,329,749 | /s/ Matthew Sesterhenn | Matthew Sesterhenn | |
| William Blank | 9.9% | 2,329,749 | 0 | 2,329,749 | /s/ William Blank | William Blank |